AMRZ Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- 18.45
- PEG ratio
- 1.42
- P/B
- 2.26
- P/S (TTM)
- 2.48
- EV/EBITDA
- 12.82
Profitability & growth
- ROE (TTM)
- 10.1%
- Operating margin
- -3.7%
- Revenue growth YoY
- 4.7%
- Dividend yield
- 0.8%
- Beta
- —
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Amrize Ltd
Company profileAmrize Ltd (AMRZ) is a cutting-edge technology firm revolutionizing the digital health and wellness sector by leveraging advanced technologies and data-driven solutions to enhance healthcare delivery. Focused on improving patient outcomes and expanding healthcare accessibility, Amrize is committed to extensive research and development that caters to the escalating demand for scalable health innovations. Its strategic initiatives and robust product offerings position the company as a significant contributor to the transformation of modern healthcare systems, making it a compelling investment…
Classification
- Sector
- Basic Materials
- Industry
- Building Materials
- Exchange
- NYSE
- Country
- USA
- Currency
- USD
Company profile
- HQ
- GRAFENAUWEG 8, ZUG, SWITZERLAND
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Educational content · Not investment advice or recommendations
We're educators, not advisors. Your decisions are your own. Disclaimer
I'm your AI thinking companion for the markets — I can help you explore and learn, but I'm not a financial advisor. Everything here is educational. Disclaimer